Regenxbio (RGNX) Total Liabilities (2014 - 2026)
Regenxbio (RGNX) posted quarterly Total Liabilities of $350.3 million for Q4 2025, up 69.77% year-over-year from $206.3 million in Q4 2024, and down 3.7% quarter-over-quarter from $363.8 million in Q3 2025.
Regenxbio (RGNX) Total Liabilities (2014 - 2026) Analysis & Trends
Regenxbio's Total Liabilities history runs 12 years deep, the most recent figure standing at $350.3 million for Q4 2025.
- In Q4 2025, Total Liabilities rose 69.77% year-over-year to $350.3 million; the TTM figure through Dec 2025 stood at $350.3 million (up 69.77% YoY), while the FY2025 annual figure was $350.3 million, up 69.77% from the prior year.
- Total Liabilities for Q4 2025 stood at $350.3 million, down from $363.8 million in the prior quarter.
- The five-year high for Total Liabilities was $367.3 million in Q2 2025, with the low at $206.3 million in Q4 2024.
- The 5-year median for Total Liabilities is $318.5 million (2022), against an average of $295.6 million.
- The sharpest annual moves came in 2021 and 2024: Total Liabilities surged 642.14% in 2021, then retreated 21.31% in 2024.
- Regenxbio's Total Liabilities stood at $349.6 million in 2021, then declined by 9.31% to $317.1 million in 2022, then slipped by 17.3% to $262.2 million in 2023, then declined by 21.31% to $206.3 million in 2024, then surged by 69.77% to $350.3 million in 2025.
- Business Quant data shows RGNX's Total Liabilities at $350.3 million in Q4 2025, $363.8 million in Q3 2025, and $367.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 314.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 314.85 Mn |
| Dec 31, 2025 | 350.30 Mn |
| Sep 30, 2025 | 363.75 Mn |
| Jun 30, 2025 | 367.35 Mn |
| Mar 31, 2025 | 216.73 Mn |
| Dec 31, 2024 | 206.34 Mn |
| Sep 30, 2024 | 217.70 Mn |
| Jun 30, 2024 | 221.11 Mn |
| Mar 31, 2024 | 238.55 Mn |
| Dec 31, 2023 | 262.23 Mn |
| Sep 30, 2023 | 270.69 Mn |
| Jun 30, 2023 | 276.60 Mn |
| Mar 31, 2023 | 282.69 Mn |
| Dec 31, 2022 | 317.07 Mn |
| Sep 30, 2022 | 319.97 Mn |
| Jun 30, 2022 | 322.93 Mn |
| Mar 31, 2022 | 335.70 Mn |
| Dec 31, 2021 | 349.61 Mn |
| Sep 30, 2021 | 338.98 Mn |
| Jun 30, 2021 | 329.16 Mn |